4548.T
SEIKAGAKU CORPORATION
プライム · 医薬品 · 医薬品 · JP
JPY 705.00
−0.14%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 36.6B | 36.6B | 39.4B | 36.2B | 33.5B |
| Cost of Revenue | 5.0B | 20.7B | 20.2B | 19.3B | 15.4B |
| Gross Profit | 3.7B | 16.0B | 19.2B | 16.9B | 18.0B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 4.1B | 16.6B | 17.8B | 16.4B | 15.9B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 4.1B | 16.6B | 17.8B | 16.4B | 15.9B |
| Cost and Expenses | 37.3B | 37.3B | 38.0B | 35.8B | 31.3B |
| Operating Income (EBIT) | (660.0M) | (660.0M) | 1.3B | 433.0M | 2.1B |
| Non-Operating | |||||
| Interest Income | 25.0M | 110.0M | 162.0M | 150.0M | 51.0M |
| Interest Expense | 1.0M | 9.0M | 4.0M | 4.0M | 5.0M |
| Net Interest Income | 24.0M | 101.0M | 158.0M | 146.0M | 46.0M |
| Other Non-Op Income/Expense | 232.0M | 2.3B | 600.0M | 1.3B | 955.0M |
| Non-Operating Income (excl Interest) | 248.0M | 2.3B | 729.0M | 1.2B | 916.0M |
| EBT (Pre-Tax Income) | (132.0M) | 1.5B | 1.9B | 1.7B | 3.1B |
| Income Tax Expense | 67.0M | 36.0M | 718.0M | (495.0M) | 832.0M |
| Bottom Line | |||||
| Net Income | 1.5B | 1.5B | 1.2B | 2.2B | 2.2B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.5B | 1.5B | 1.2B | 2.2B | 2.2B |
| Per Share | |||||
| Basic EPS | ¥27 | ¥27 | ¥22 | ¥40 | ¥40 |
| Diluted EPS | ¥27 | ¥27 | — | — | — |
| Revenue Per Share | ¥671 | ¥671 | ¥721 | ¥664 | ¥606 |
| Shares | |||||
| Basic Shares Outstanding | 54.6M | 54.6M | 54.6M | 54.6M | 55.2M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 1.3B | 3.1B | 1.9B | 3.3B |
| D&A | — | 2.0B | 1.8B | 1.5B | 1.2B |
| EBIT | (660.0M) | (660.0M) | 1.3B | 433.0M | 2.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026